HIV (Human Immunodeficiency Virus)

The current standard is 'treat immediately' — ART is recommended on the day of diagnosis regardless of CD4 count. Early treatment preserves immune function, prevents transmission, and reduces long-term complications. The INSIGHT START trial proved that waiting was worse. Your HIV doctor will prescribe your first regimen the day you're diagnosed or very shortly after. Don't delay.

HIV medications are expensive at list price, but no one in the US should be paying list price. If uninsured: apply for ADAP (AIDS Drug Assistance Program) immediately through your state health department. If commercially insured: manufacturer co-pay programs (Gilead Advancing Access, ViiV Compass) bring costs to $0/month. Contact an AIDS Service Organization (ASO) in your area — they navigate this for free.

Primary care can manage stable HIV, but your initial workup, resistance testing, and regimen selection should involve an HIV specialist or infectious disease physician. They'll order a baseline resistance test (HIV genotype) to ensure your first regimen is effective. HIV clinics at academic centers, community health centers (FQHCs), and Ryan White-funded clinics provide comprehensive, often sliding-scale care.

Two lab values define HIV management: CD4 count (your immune strength — normal is 500–1500 cells/mm³; treatment goal is to restore and maintain >500) and viral load (copies of HIV RNA per mL of blood — treatment goal is 'undetectable,' typically <20–200 copies/mL). You'll check these every 3 months initially, then every 6 months once stable. Undetectable viral load means ART is working and you cannot transmit HIV to partners (U=U).

An HIV diagnosis is a mental health event, not just a medical one. Organizations like The Well Project, POZ magazine community, and local AIDS Service Organizations provide peer support, navigation services, and community. Research consistently shows social support is one of the strongest predictors of treatment adherence and long-term outcomes. You're not alone — 1.2 million Americans are managing this successfully.

HIV (Human Immunodeficiency Virus) attacks and destroys CD4 T-cells — the immune cells that coordinate the body's response to infection. Untreated, HIV progresses through three stages: acute HIV infection (flu-like illness 2–4 weeks after exposure), chronic HIV infection (years of gradual immune decline), and AIDS (acquired immunodeficiency syndrome) — defined as a CD4 count below 200 cells/mm³ or an AIDS-defining illness. With modern antiretroviral therapy, HIV-positive people can live decades without ever progressing to AIDS. HIV is transmitted through blood, breast milk, and sexual fluids — not through casual contact.

Antiretroviral therapy (ART) is the combination of HIV medications that suppresses the virus to undetectable levels. ART does not cure HIV — it prevents the virus from replicating. Drug classes include: Integrase Strand Transfer Inhibitors (INSTIs) — block HIV integrase enzyme (bictegravir, dolutegravir, cabotegravir); NRTIs — block reverse transcriptase using nucleoside analogues (tenofovir, emtricitabine, lamivudine); NNRTIs — non-nucleoside reverse transcriptase inhibitors (rilpivirine, efavirenz); PIs — protease inhibitors (darunavir); and the novel capsid inhibitor lenacapavir. Modern first-line regimens typically combine an INSTI with 1–2 NRTIs in a single daily pill, achieving undetectable viral load in 95%+ of adherent patients within 6 months.

HIV antiretroviral therapy is expensive. Without insurance, monthly costs run: Single-tablet daily regimens (Biktarvy, Dovato, Triumeq): $3,000–$4,000/month ($36,000–$48,000/year); Long-acting injectables (Cabenuva): $4,000–$5,000/month equivalent; Older regimens (generic components): $500–$1,500/month. However, uninsured patients rarely pay list price. The AIDS Drug Assistance Program (ADAP), administered through Ryan White, provides free or low-cost HIV medications based on income. Manufacturer patient assistance programs also cover uninsured patients fully in most cases. No HIV-positive patient in the US should forgo treatment due to cost.

ADAP is a federally funded, state-administered program that provides free or subsidized HIV medications to low-income individuals who are uninsured or underinsured. It's part of the Ryan White HIV/AIDS Program, the largest federal program specifically for people living with HIV. Every state has an ADAP, though formularies and income limits vary. Income eligibility is generally 100–400% of the federal poverty level (FPL), but some states are more generous. To apply, contact your state health department's HIV/AIDS program or an AIDS Service Organization (ASO).

U=U (Undetectable = Untransmittable) is a scientifically validated principle: HIV-positive people on effective antiretroviral treatment who maintain an undetectable viral load (typically <200 copies/mL) have effectively zero risk of transmitting HIV to sexual partners. This was established by landmark studies including PARTNER1, PARTNER2, and HPTN 052 — which together followed thousands of serodiscordant couples and found zero linked transmissions when the HIV+ partner had an undetectable viral load.

PrEP (Pre-Exposure Prophylaxis) is a medication regimen for HIV-negative people that, taken consistently, prevents HIV infection with greater than 99% efficacy. FDA-approved options: Truvada (tenofovir disoproxil fumarate/emtricitabine) — daily oral pill; Descovy (tenofovir alafenamide/emtricitabine) — daily oral pill; Apretude (cabotegravir injectable) — given every 2 months by injection, superior efficacy to oral PrEP. PrEP is recommended for HIV-negative people with substantial risk: MSM without consistent condom use, people with HIV-positive partners, people who inject drugs sharing equipment, or recent STI diagnosis.

Yes. With proper treatment, HIV-positive parents can have HIV-negative babies through Prevention of Mother-to-Child Transmission (PMTCT). Key elements: the HIV+ parent maintains an undetectable viral load during pregnancy; ART is continued throughout pregnancy and delivery; the baby receives antiretroviral medication for 4–6 weeks after birth. With this protocol, the risk of mother-to-child HIV transmission drops from ~25% (untreated) to less than 1%.